Akamis Bio
Abingdon
About Akamis Bio
Akamis Bio is a clinical-stage oncology company whose mission is to use its groundbreaking Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform to improve the lives of cancer patients. To accomplish this goal, the company is developing a portfolio of solid tumor-targeted T-SIGn® therapeutics that will allow a patient's immune system to recognize, attack, and clear their cancer.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $192.5M
- Funding stage: Early Stage Venture
- Last round: Series A (Dec 2024)
- Website: akamisbio.com
- Phone: +44 (0)1235 835328
Industries & Categories
Biotechnology, Health Care, Oncology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/akamis-bio-8783 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.